中风醒神合剂治疗急性缺血性脑卒中风痰瘀阻证临床评价及对NT-pro-BNP、MMP-9、ICAM-1、MCP-1影响研究  

Clinical Evaluation of Zhongfeng Xingshen Mixture(中风醒神合剂)in the Treatment of Acute Ischemic Stroke with Wind Phlegm and Stasis Syndrome and Its Effect on NT-pro-BNP,MMP-9,ICAM-1,MCP-1

作　　者：王丽波 杨泽华 WANG Libo;YANG Zehua(Dandong Hospital of Traditional Chinese Medicine,Dandong 118000,Liaoning,China)

机构地区：[1]丹东市中医院,辽宁丹东118000

出　　处：《辽宁中医药大学学报》2022年第3期15-18,共4页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：杨泽华全国名老中医药专家传承工作室建设项目(国中医药人教函[2019]41号)。

摘　　要：目的探究中风醒神合剂治疗急性缺血性脑卒中(acute ischemic stroke,AIS)风痰瘀阻证的临床评价及对N末端脑钠肽前体(NT-pro-BNP)、基质金属蛋白酶-9(MMP-9)、细胞间黏附分子-1(ICAM-1)、单核细胞趋化蛋白-1(MCP-1)影响研究。方法回顾性分析,选取2019年1月—2020年1月于丹东市中医院神经内科确诊为AIS患者116例为研究对象,根据患者及家属治疗意愿分为常规西医西药治疗组(对照组)47例及联用中医中风醒神合剂治疗组(研究组)69例,观察并分析两组患者的NT-pro-BNP、MMP-9、ICAM-1、MCP-1水平变化及神经功能改善、不良反应发生等情况。结果经治疗,研究组患者的美国国立卫生研究院卒中量表(NIHSS)评分、中医证候积分均明显低于对照组患者(P<0.05),研究组患者的临床总有效率(92.75%)显著优于对照组患者(82.98%)(P<0.05),研究组患者的NT-pro-BNP、MMP-9、ICAM-1、MCP-1明显低于对照组患者(P<0.05);治疗后,两组患者均未发生明显的不良反应事件。结论中风醒神合剂治疗AIS的临床疗效显著,能够明显降低NTpro-BNP、MMP-9、ICAM-1、MCP-1水平,改善神经功能缺损,临床症状得以缓解,提高患者的生活质量,且临床安全性较高。Objective To explore the clinical evaluation of Zhongfeng Xingshen Mixture(中风醒神合剂)in the treatment of acute ischemic stroke(AIS)with of wind phlegm and blood stasis syndrome and the N-terminal pro-brain natriuretic peptide(NT-proBNP),matrix metallopeptidase-9(MMP-9),intercellular cell adhesion molecule-1(ICAM-1),monocyte chemoattractant protein-1(MCP-1)impact study.Methods A retrospective analysis was conducted.116 patients diagnosed with AIS in the department of neurology,Dandong Hospital of Traditional Chinese Medicine from January 2019 to January 2020 were selected as the research objects.The patients and their families were divided into the conventional Western medicine treatment group(control group)47 cases and 69 cases in the combined Chinese medicine Zhongfeng Xingshen Mixture treatment group(research group),to observe and analyze the changes in NTpro-BNP,MMP-9,ICAM-1,MCP-1 levels and neurological improvement of the two groups of patients and the occurrence of adverse reactions.Results After treatment,the NIHSS score and TCM syndrome scores of the study group were significantly lower than those of the control group(P<0.05),and the total clinical effective rate(92.75%)of the study group was significantly better than that of the control group(82.98%)(P<0.05).The NT-pro-BNP,MMP-9,ICAM-1 and MCP-1 of the study group were significantly lower than those of the control group(P<0.05);after treatment,both groups had no obvious adverse events occurred.Conclusion Zhongfeng Xingshen Mixture has a significant clinical effect in the treatment of AIS.The levels of NT-pro-BNP,MMP-9,ICAM-1 and MCP-1 are significantly reduced,neurological deficits are improved,clinical symptoms are relieved,and the quality of life of patients is improved,and the clinical safety is high.

关 键 词：急性缺血性脑卒中 风痰瘀阻证 中风醒神合剂 N末端脑钠肽前体 基质金属蛋白酶-9 细胞间黏附分子-1 单核细胞趋化蛋白-1 临床评价 

分 类 号：R743.3[医药卫生—神经病学与精神病学]